No Data
No Data
Individual investor, Yugetsu Yuken: The focus on australian small/mid cap stocks is reviving, drawing even more attention to biotech stocks! [FISCO Social Reporter]
The following is a comment written by individual investor "Yuugentei Tamaki" (Blog: Profitable Stock Information "The Cat's Husband's Ceilingless Stock") of the FISCO Social Reporter. At FISCO, we strive to collaborate with individuals who actively disseminate information in order to provide a wider range of information to investors. ----------- * After the news that the Ministry of Economy, Trade and Industry will compile an action plan to expand the biotechnology industry on September 2, 2024 at 13:00, biotech stocks have a wide range of
Volume change rate ranking (10 o'clock) - The Imperial Hotel, Feed One, etc. ranked in.
*In the volume change rate ranking, you can understand the interests of market participants, such as trends in trading activities, by comparing the average trading volume for the past 5 days with the trading volume on the day of the publication. Top volume change rate [as of August 26, 10:32] (compared to the average trading volume for the past 5 days) Stock code Company name Volume 5-day average volume Volume change rate Stock price change rate<133A> GX Super Short Rice 156,450 18,888.661 265.98% -0.0*
Volume Change Rate Ranking (9:00 am) - Fanpep, MagMagu, etc. ranked in
In the volume change rate ranking, you can understand the market participants' interests such as trend of speculation by comparing the average volume of the past 5 days with the volume on the delivery day. Top Volume Change Rates [As of August 22, 9:32] (Comparison with 5-day average volume) Stock Code Stock Name Volume 5-day Average Volume Volume Change Rate Price Change Rate <7857> Seki 400 107185.08 299.34% 0% <8836>
Volume change rate ranking (10 o'clock) - Korowaido, Career DC, etc. ranked in.
In the volume change ratio ranking, by comparing the volume of the last 5 days with the volume on the delivery day, you can understand the market participant's interest in trends such as stock picking. Top gainers in volume change ratio [As of 10:32 on August 21] (comparison with average volume of the last 5 days) Stock code Stock name Volume Average volume of last 5 days Volume change ratio Change in stock price <7616> Color Wide 2849400 522640.2 254.55% -0.0
Promoting pipeline expansion through joint research in the first quarter of Nano MRNA, adding a contract model.
On the 9th, NANO MRNA <4571> announced its consolidated financial results for the first quarter of the 2025 fiscal year (April-June 24). It did not record revenue (the same period last year had revenue of 0.058 billion yen), had an operating loss of 0.189 billion yen (loss of 0.304 billion yen in the same period last year), had an ordinary loss of 0.155 billion yen (loss of 0.285 billion yen in the same period last year), and had a quarterly net loss attributable to parent company shareholders of 0.156 billion yen (loss of 0.285 billion yen in the same period last year). In this first quarter, it shifted from previous collaborative and drug discovery biotech venture models.
Nano mRNA has signed a joint research agreement with Senshu Pharmaceutical to develop mRNA drugs for ophthalmic diseases.
NANO MRNA <4571> announced on the 9th that it has entered into a joint research agreement with Chijyu Pharmaceutical on mRNA drug discovery targeting ophthalmic diseases. The company specializes in non-clinical development of mRNA drug discovery and has created valuable IP. Chijyu Pharmaceutical is a specialty pharma in the field of ophthalmology with unique ideation skills and research and development. Both companies have been conducting basic research on the creation of eye disease treatments using mRNA. This time, they are exploring the creation of mRNA drugs for ophthalmic medicine targets.
No Data
No Data